Monopar Therapeutics
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers. Its pipeline centers on ALXN1840, a late-stage Wilson disease asset, and MNPR-101 radiopharmaceutical programs for imaging and treating solid tumors.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLate-stage investigational treatment for Wilson disease, centered on ALXN1840.
MNPR-101-based diagnostic imaging and dosimetry programs for advanced cancers.
Therapeutic radioisotope programs designed to treat uPAR-expressing solid tumors.
Earlier-stage assets and internal R&D to expand the oncology pipeline.
In-licensing, collaboration, and regulatory development activities supporting the pipeline.
Customers
Monopar does not yet sell approved products, so its near-term customers are clinical investigators, trial sites, regulators, and collaboration partners rather than end-market patients. If approved, its commercial buyers would be physicians, hospitals, and specialty pharmacies treating Wilson disease or advanced cancer patients. The company also depends on licensors and strategic partners such as Alexion/AstraZeneca for asset access and development rights.
FDA, CROs, and trial sites that enable development and approval of ALXN1840 and MNPR-101 programs.
Specialist physicians and treatment centers that would prescribe ALXN1840 if approved.
Hospitals and oncology centers that could use MNPR-101 imaging or therapeutic agents.
Pharma partners that may out-license, co-develop, or commercialize assets with Monopar.
Strategy
Monopar’s strategy is to advance a small number of high-value assets through late-stage development, starting with an NDA package for ALXN1840 in Wilson disease. It is also building a radiopharmaceutical platform around MNPR-101, aiming to create both diagnostic and therapeutic products for aggressive cancers. The company relies on in-licensing, clinical execution, and intellectual property protection to create optionality for partnering or commercialization.
Regulatory approval is the key value inflection point for the Wilson disease asset.
The imaging and therapeutic programs could create a second value driver in oncology.
As a pre-revenue biotech, Monopar must fund R&D until approval or partnering monetization.
Geography
Monopar is headquartered in the United States and its development, financing, and clinical operations are primarily U.S.-based. The company’s programs are intended for U.S. regulatory approval first, though its management cites prior experience with FDA and EMA submissions and global commercialization. Geography matters mainly through U.S. clinical trial execution, FDA filing strategy, and potential future expansion into Europe or other markets.
Risks
Monopar is a pre-revenue biotech, so its business depends on successful clinical development, regulatory approval, and access to capital before any product sales. The main risks are trial failure, delays in FDA review, IP disputes, and dilution or restrictive terms from future financing or partnering. Radiopharmaceutical development also carries manufacturing, safety, and competitive risks typical of oncology drug development.
Pipeline value depends on positive trial outcomes for ALXN1840 and MNPR-101 programs.
The company has not generated product revenue and expects to fund operations externally.
Commercialization depends on FDA approval of a late-stage rare disease asset and oncology candidates.
Exposure: NDA filing for ALXN1840
Competing therapies could limit uptake or reduce the commercial potential of the pipeline.
Exposure: Wilson disease and oncology markets
Radiopharmaceutical and clinical supply chains are complex and must meet quality standards.
Exposure: Clinical and future commercial supply
Accounting
Judgemental itemsCosts are estimated based on progress of third-party trial work, affecting R&D timing and comparability.
Impact: Can cause quarter-to-quarter swings in R&D expense
Equity awards to employees and directors materially affect G&A and operating loss.
Impact: Can inflate non-cash operating expenses
Cash and investments generate interest income that partially offsets operating losses.
Impact: Affects net loss and liquidity presentation
Capital raises are a core funding source and can materially dilute shareholders.
Impact: Changes share count and cash runway
Similar listed companies
Publicly listed companies with a comparable business focus.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Allarity Therapeutics, Inc.
ALLR · Pharmaceutical Preparations
Cullinan Therapeutics, Inc.
CGEM · Biological Products, (No Diagnostic Substances)
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Last updated: 24/09/2026